Эффективность и переносимость помалидомида у больных с рецидивирующими/рефрактерными формами множественной миеломы

Эффективность и переносимость помалидомида у больных с рецидивирующими/рефрактерными формами множественной миеломы

Автор: Бессмелъцев С.С.

Журнал: Вестник гематологии @bulletin-of-hematology

Рубрика: Передовая статья

Статья в выпуске: 4 т.13, 2017 года.

Бесплатный доступ

Использование новых подходовв лечении рецидивов и рефрактерных форммножественной миеломы (ММ) привело к существенному улучшению показателей общейвыживаемости больных, достижению качественного ответа и более длительной ремиссиипо сравнению с пациентами, получавшими стандартную химиотерапию. Эти изменения связаны,главным образом, с применением новых препаратов: бортезомиба, талидомида, леналидомида, каждый из которых обладает выраженнойпротивоопухолевой активностью. Однако, еслибольные не отвечают на бортезомиб и иммуномодуляторы, прогноз ухудшается. Представленный обзор посвящен вопросам терапевтической эффективности, безопасности и особенностям практического применения помалидомида. Помалидомид - иммуномодулирующий препарат 3-го поколения. В обзоре представлены результаты основных клинических исследований по тестированию комбинации помалидомидас низкими дозами дексаметазона. Отмечено, что комбинация помалидомида с дексаметазоном эффективна у пациентов с рецидивами и рефрактерными формами ММ, получавших ранеебортезомиб и леналидомид. Обсуждаются проблемы создания на основе помалидомида новыхрежимов лечения рецидивирующей и рефрактерной ММ. В 2015 г. помалидомид в сочетаниис дексаметазоном зарегистрирован в России для лечения больных с рецидивами и рефрактернойММ, получивших не менее 2 циклов терапии,включая леналидомид и бортезомиб, у которых отмечалось прогрессирование болезни на фоне последнего лечения.

Еще

Множественная миелома, рецидив, рефрактерность, помалидомид, дексаметазон

Короткий адрес: https://sciup.org/170172520

IDR: 170172520

Список литературы Эффективность и переносимость помалидомида у больных с рецидивирующими/рефрактерными формами множественной миеломы

  • Бессмельцев С. С., Абдулкадыров К. М. Множественная миелома: руководство для врачей. — М: МК. — 2016. — 504 с.
  • Ludwig H., Boleyack V., Crowleu J. et al. Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. // J Clin Oncol. — 2010. — Vol. 28. — 1599-1605.
  • Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. // Blood. — 2008. — Vol. 111, N5. — P. 2521-2526.
  • Barlogie B., Attal M., Crowley J. et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. // J Clin Oncol. — 2010. — Vol. 28, N7. — P. 1209-1214.
  • Facon T., Dimopoulos M. A., Dispenzieri A., et al. Initial Phase 3 Results of The First (Frontline Investigation of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients Ineligible for Stem Cell Transplantation (SCT)// Blood. — 2013. — Vol. 122, N21. — Abstr. 2.
  • Kumar S. K., Lee J. H., Lahuerta J. J. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. // Leukemia. — 2012. — Vol. 26, N1. — P. 149-157.
  • Lopez-Girona A., Mendy D., Ito T., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. // Leukemia. — 2012. — Vol. 26. — P. 2326-2335.
  • Zhu D., Corral L. G., Fleming Y. W., Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. // Cancer Immunol Immunother. — 2008. — Vol. 57, N12. — P. 1849-1859.
  • Davies F. E., Raje N., Hideshima T. et. al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. // Blood. — 2001. — Vol. 98. — P. 210-216.
  • Escoubet-Lozach L., Lin I. L., Jensen-Pergakes K. et. al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. // Cancer Res. — 2009. — Vol. 69. — P. 7347-7356.
  • Li S., Pal R., Monaghan S. A. et al. IMiD immunomodulatory compounds block C/EBPP translation through eIF4E down-regulation resulting in inhibition of MM. // Blood. — 2011. — Vol. 117. — P. 5157-5165.
  • Rychak E, Mendy D, Miller K, et al. Overcoming resistance: the use of pomalidomide (Pom) and dexamethasone (Dex) in resensitizing lenalidomide (Len)-resistant multiple myeloma (MM) cells. // Haematologica. — 2011. — Vol. 96. — Vol. s1. — P. s126. [abstract P-328.
  • Bolzoni M., Abeltino M., Storti P. et. al. The immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules. // Blood. — 2010. — Vol. 116. — P. 201 [abstract 448].
  • Mitsiades N., Mitsiades C. S., Poulaki V. et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. // Proc Natl Acad Sci USA. — 2002. — Vol. 99, № 22. — P. 14374-14379.
  • Verhelle D., Corral L. G., Wong K. et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. // Cancer Res. — 2007. — Vol. 67, № 2. — P. 746-755.
  • Schey S., Ramasamy K. Pomalidomide therapy for myeloma. // Expert Opin Investig Drugs. — 2011. — Vol. 20. — P. 691-700.
  • Terpos E., Kanellias N., Christoulas D. et al. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. // OncoTargets and Therapy. — 2013. — Vol. 6. — P. 531-538.
  • Schey S. A., Fields P., Bartlett J. B. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. // J Clin Oncol. — 2004. — Vol. 22. — P. 3269-3276.
  • Streetly M. J., Gyertson K., Daniel Y. et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. // Br J Haematol. — 2008. — Vol. 141, № 1. — P. 41-51.
  • Richardson P. G., Siegel D. S., Vij R. et al. Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. // ASH Annual Meeting Abstracts. — 2011. — Vol. 118. — P. 634.
  • Richardson P. G., Siegel D., Baz R. et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. // Blood. — 2013. — Vol. 121, № 11. — P. 1961-1967.
  • Lacy M. Q., Kumar S. K., LaPlant B.R. et al. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. // ASH Annual Meeting Abstracts. — 2012. — Vol. 120. — P. 201.
  • Leleu X., Attal M., Arnulf B. et al. High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02. // ASH Annual Meeting Abstracts. — 2011. — Vol. 118. — P. 812.
  • Leleu X., Attal M., Arnulf B. et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Published online before print January 14, 2013, doi: 10.1182/blood-2012-09-452375. // Blood. — 2013. — P. 121, № 11. — P. 1968-1975.
  • Vij R., Richardson P. G., Jagannath S. et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). // J Clin Oncol. — 2012. — Vol. 30 (suppl; abstr 8016).
  • Richardson P. G., Siegel D. S., Vij R. et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study//Blood. — 2014. — Vol. 123. — P. 1826-1832.
  • San-Miguel J.F., Weisel K. C., Moreau Ph. et al. MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). // 2013 ASCO Annual Meeting. J Clin Oncol. — 2013. — Vol. 31 (Suppl.), Abstr. 8510).
  • Leleu X., Karlin N., Marco M. et al. Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma with del(17p) and/or translocation t(4;14)// Blood. — 2013. — Vol. 122, Abstr. 689.
  • Dimopoulos M. A., Weisel K. S., Song K. W. et al. Cytogenetics and long-term survival patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. //Haematologica. — 2015. — Vol. 100. — P. 1327-1333.
  • Dimopoulos M. A., Palumbo A., Corradini P. et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. //Blood. — 2016. — Vol. 128. — P. 497-503.
  • Morgan G., Palumbo A., Dhanasiri S. et al. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 for pomalidomide and low-dose dexamethasone. // Br J Haematol. — 2015. — Vol. 168. — P. 820-823.
  • Palumbo A., Larocca A., Montefusco V. et al. Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. // ASH Annual Meeting Abstracts. — 2012. — Vol. 120. — P. 446.
  • Baz R. C., Martin T. G., Lin H. et al. Randomized multicenter phase 2 study ofpomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. // Blood. — 2016. — Vol. 127, N21. — P. 2561-2568.
  • Shah J. J., Zonder J. A., Cohen A. et al. The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study. // ASH Annual Meeting Abstracts. — 2012. — Vol. 120. — P. 449.
  • Lacy M. Q. M.Q., LaPlant B.R., Laumann K. M. et al. Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma// Blood. — 2014. — Vol. 124. — P. 304.
  • Shah J. J., Stadtmauer E. A., Abonour R. et al. A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. // ASH Annual Meeting Abstracts. — 2012. — Vol. 120. — P. 74.
  • Rosenbaum C.A., Stephens L. A., Kukreti V. et al. Phase 1/2 study of carfilzomib pomalidomide, and dexamethasone (KRd) in patients with relapsed/refractory multiple myeloma: a multiple myeloma research consortium multicenter study// ASCO Meeting Abstracts, — 2016. — Vol. 34. — P. 8007.
  • Jakubowiak A. J., Rosenbaum C. A., Stephens L. et al. Final results of phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPD) in patients with relapsed/refractory multiple myeloma: a multi-center MMRC study// haematologica. — 2017. — Vol. 102, s1. — P. 271 (Abstr. P680) (22nd Congress of the European Hematology Association Madrid, Spain, June 22-25, 2017).
  • Mark T. M., Boyer A., Rossi A. C. et al. ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. // Blood (ASH Annual Meeting Abstracts) — 2012. — P. 120 (Abstract 77).
  • Ajai Chari, Attaya Suvannasankha, Joseph W. et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma// Blood 2017. — Vol. 130, N8. — P. 974-981.
  • Sehgal K, Das R, Zhang L, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets//Blood. — 2015. — Vol. 125, N26. — P. 40424051.
  • Badros A., Hyjek E., Ma N. et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/ refractory multiple myeloma. // Blood. — 2017. — Vol. 130. — P. 1189-1197
  • Weisel K., Dimopoulos M. A., Cavo M. et al. Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010).// Blood (ASH Annual Meeting Abstracts). — 2014. — Vol. 124, N21: Abstr. 4755.
  • Sonneveld P., Weisel K., van de Donk N. et al. MM-013 phase 2 multicenter study ofpomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment// haematologica. — 2017. — Vol. 102, s1. — P. 113 (Abstr. P343) (22nd Congress of the European Hematology Association Madrid, Spain, June 22-25, 2017).
  • Short K. D., Rajkumar S. V., Larson D. et al. Incidence ofextramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. // Leukemia. — 2011. — Vol. 25, N6. — P. 906-908.
  • Moreau P., San Miguel, Sonneveld P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up// Ann. Oncology. — 2017. — Vol. 0. — P. 1-11.
  • Kumar A. K., Callander S. N., Alsina M. et al. NCCN Guidelines Version 3.2017 — November 28, 2016 (NCCN. org).
  • Richardson P., Bensmaine A., Doerr T. et al. MM-007: a phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX) [PVD] versus BORT and LoDEX (VD) in subjects with relapsed of refractory multiple myeloma. // J Clin Oncol. — 2015. — Vol. 33 (suphl; Abstr. TPS8610).
  • San-Miguel J.F., Mateos M. — V. How to treat a newly diagnosed young patient with multiple myeloma// Hematology (American Society of Hematology Education Program Book, New Orleans, Louisiana, December 508, 2009). — 2009. — P. 555-565.
  • Palumbo A., Rajkumar S. V., Dimopoulos M. A. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.// Leukemia. — 2008, — Vol. 22, N2. — P. 414-423.
  • Kristinsson S. Y. Thrombosis in multiple myeloma.// Hematology Am Soc Hematol, Educ Program. — 2010. — Vol. 1. — P. 437-444.
  • Dimopoulos M. A., Leleu X., Palumbo A. et al. Expert panel consensus statement on the optimal use pomalidomide in relapsed and refractory multiple myeloma//Leukemia. — 2014. — Vol. 28. — P. 1583-1586.
  • Cooper K. L., Madan J., Whyte S. et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systemic review and meta-analysis.// BMC Cancer. — 2011. — Vol. 11. — P. 404-413.
  • Hanaizi Z., Flores B., Hemmings R. et al. The European Medicines Agency Review of Pomalidomide in Combination with Low-Dose Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use// Oncologist. — 2015. — Vol. 20, N3. — P. 329-334.
Еще
Статья научная
SciUp 2024 © 2024 ©